This continued progression, despite IL-6 inhibition, indicates that targeting IL-6 alone may not suffice to manage the hematological aspects of VEXAS syndrome, underscoring the necessity for combination therapies or alternative approaches to address both inflammatory and hematological manifestations effectively. The gene discussed is IL6; the disease is VEXAS syndrome.